I try not to overly speculate on the unknowable - we've heard nothing from company on any delays/requests for further information. As MikesLM pointed out, they are still within their own maximum allotted timescales. I am simply pointing out that its overdue by typical/average timescales and company expectations.
It is, as said, just another version of CelGro - in tendon application (SmrtGraft) - and the TGA has already approved CelGro for bone (Striate) and nerve (Remplir), so I would be surprised if the third application was facing any difficulties.
OCC Price at posting:
$1.22 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)